Applying AI-Driven Biosimulation to Drug Discovery
Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…
CertaraJune 2, 2026
Certainty US 2026 recap: advancing model-informed drug development right from the start
This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…
CertaraMay 26, 2026
Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…
CertaraMay 21, 2026
MIDD is Transforming Drug Development
Recorded live at the US Certainty 2026 client conference in Boston, Certara clients who are…
CertaraMay 21, 2026
How to Leverage PBPK Modeling and Simulation in Drug Research and Development
Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…
CertaraMay 12, 2026
Designing Drug Development Programs for Reimbursement Success
Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…
CertaraMay 7, 2026
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome
A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…
CertaraMay 7, 2026
